Day 1 :
Keynote Forum
Dariusz Borys, Loyola University Chicago, USA
Loyola University Chicago, USA
Keynote: Can we predict neoadjuvant therapy response in patients with osteosarcoma?
Time : 9:45-10:30AM
Biography:
Dr. Dariusz Borys is an Associate Professor of Pathology and Orthopaedic Surgery, head of Orthopaedic and Pediatric Pathology and Director of Digital Pathology at Loyola University Chicago. He received his Doctor of Medicine from the University of Wroclaw, Poland in 1994 and completed a residency program in anatomic pathology at County General Hospital in Wroclaw, Poland in 1995. He completed his postdoctoral research at the University of Arizona, Tucson, Arizona in 1998. He continued on with and completed residency training in both anatomic pathology and clinical pathology at University of Illinois at Chicago in 2001. He received a Pediatric Pathology Fellowship at New York University, New York, New York in 2005 and followed that with an Orthopedic Pathology Fellowship at NYU Hospital for Joint Diseases, New York, New York in 2006. After completing his fellowships, Dr. Borys become faculty member in the rank of assistant professor at University of California and then he finally moved to Loyola University Chicago in 2013. At LUMC he is appointed as an Associate Professor of Pathology and Orthopaedic Surgery and is serving as the head of orthopaedic and pediatric pathology and director of digital pathology. Currently Dr. Borys' research focuses on the molecular markers in diagnostic, prognostic and targeted therapy in osteosarcoma.
Abstract:
Osteosarcoma (OS) is a malignant primary tumor of bone affecting adolescents and young adults. There are few if any molecular markers to predict its behavior and prognosis. In our study we investigated the relationship of expression of different molecular markers in osteosarcoma tumors before treatment to pathologic necrotic response after neoadjuvant chemotherapy. In summary, deletion of RB1 (72%), gain of RUNX2 (68%), deletion of TP53 (52%), deletion 18q23 (48%) by molecular studies and p16-negative by IHC (38%) were common findings. Most abnormalities, particularly RB1 and TP53 deletions and RUNX2 gain, did not correlate with chemotherapy response. IHC p16-negative status correlated strongly with failed chemotherapy response (15/40). Alterations of 18q correlated slightly with poor response (p=0.0796). Poor response cases included 3 cases with deletion of 18q23, 3 cases with LOH for 18q23, and 1 case with copy gain (trisomy 18). Comparison of 18q genomic abnormalities in cases with a favorable versus poor response suggested a smallest region of overlap for a negative factor at 18q23. In conclusion we identified complex genotypes in the OS samples with frequent occurrence of previously identified biomarkers such as deletion RB1, deletion TP53, deletion 18q23 and gain of RUNX2. Comparison of genomic findings to p16-negative status and chemotherapy response revealed p16-negative status to be the best overall indicator of a poor chemotherapy response, with the poorest responders being both p16 negative and altered for 18q23. Additional studies are warranted to validate these findings and further characterize the role of CDKN2A and other factors that influence response to therapy in osteosarcoma patients.
Keynote Forum
Lyudmila Severyanova
Kursk State Medical University, Russian Federation
Keynote: Regulatory peptides:the mechanisms of effects on the pain-induced aggressive-defensive behavior
Time : 10:30-11:15AM
Biography:
Severyanova L. Performed research at Kursk State Medical University and received her PhD at the age of 25 and later Russian "Doctor of Medicine" at the Pavlov Institute of Physiology of the Russian Academy of Sciences.Consequently : Head of the Department of Pathophysiology, Dean of the International Faculty, Professor of Pathophysiology, Honored Worker of Higher School. Scientific interest: the integration of nervous, endocrine and immune mechanisms in the systemic reactions of the body. She has published more than 50 articles in reputed journals and three monographs
Abstract:
For many years we have studied the regulatory peptides effects on the integration of nervous, endocrine and immune mechanisms in the pain-induced aggressive-defensive behavior in rats. 23analogues of the natural hypothalamic-pituitary peptides and other peptides synthesized in the Russian Academy of Sciences and "Serva" were administered in intraperitoneal and brain intraventricular injections.With the use of the modified foot-shock model the following regularities of peptide effects were revealed.( i) The key role in peptide effects is played by the L-arginine or L-lysine amino acids residues.In particular ,only the administration of arginine- containing peptides increased pain sensitivity and aggression.(ii) Binding of the tripeptide Pro-Gly -Pro to the amino acid (Arg) or oligopeptide (ACTH 4-7) essentially modifies the influence on the affective aggression. ( iii ) The intensity of aggression depends on the excitability of the brain emotional negative system more than on pain perception.This was demonstrated due to effects of encephalin analogues.( iy ) Peptide effects seemed to be dependent on the brain locus of their primary application. (y) Neuropeptide effects were more expressed in rats with the higher excitability of nociceptive, emotional,opioid and M-cholinergic systems.Since analogues of the natural peptides have been used, there is a reason to believe that obtained data make it possible to elucidate the mechanisms of the development of the pain-induced affective aggression and to develop means for its correction.
Keynote Forum
Shashikant Limbachiya
Narayana Multispeciality Hospital India
Keynote: Optimizing swallowing outcomes and management of Dysphagia in Head & Neck Cancer
Time : 11:15-12:00
Biography:
Dr Shashikant Limbachiya is super specialist (MCh) Head & Neck Onco Surgeon working in Gujarat India. After his post graduation in Master of Surgery, he did super speciality from world renowned amrita Institute, kochi. He is founder of India’s first Dysphagia society, “Deglutology Research Foundation”. His area of interests are oral,laryngeal,sinonasal, skull base, thyroid, parotid & Neck surgeries as well as Reonstructive Platic & Microvascular procedures. He has authored 6 text book chapters and several publications in reputed journals. He has presented several award/ podium papers in various international conferences.
Abstract:
Dysphagia (swallowing dysfunction) is a debilitating, depressing, and potentially life-threatening complication in cancer patients that is likely neglected. In last two decades oncological outcomes has improved with advance in surgical and radiation methods, that’s why quality of life needs to be addressed among survivors. This keynote lecture is aimed to give precise information on dysphagia in head and neck with a focus on assessment tools, prevalence, complications, and impact on quality of life. Management of swallowing dysfunctions will be covered with recent advances and available evidences in all subsites of head and neck cancers who are treated with curative surgical / chemoradiation modality.